Uscom receives US Patent notification

THE ROADHOUSE PHARMACY: Uscom Limited (ASX: UCM) has received a Notice of Allowance from the US Patents Office for a new US Patent for the non-invasive measurement of suprasystolic blood pressure.

The patent method is central to the operations of the company’s BP+ suprasystolic oscillometric blood pressure monitor.

Uscom said the BP+ has been recognized as the leading technology for the measurement and monitoring of central blood pressure in an independent study authored by hypertension researchers from Cambridge University, Cambridge, UK, Wales Heart Institute, Cardiff, UK, Weill Cornell Medical College, New York, USA and the University of California, Irvine, USA.

The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe.

“This patent is central to the operation of the Uscom BP+ suprasystolic blood pressure monitor and joins a suite of patents which protect the BP+ technology commercially in the largest medical device market in the world,” Uscom executive chairman Rob Phillips said in the company’s announcement to the Australian Securities Exchange.

“It also distinguishes BP+ from other devices using older and less effective technology.

“We are currently preparing to manufacture the Uscom BP+ and are actively establishing a new network of distribution into the specialised global BP markets.”

The BP+ device uses patent protected “suprasystolic oscillometry” to measure simply and noninvasively central blood pressure at the heart, while older methods measure the pressure in the arm or hand.

Uscom explained the BP+ measurements provide sensitive information about the health of the heart and vessels and are used to improve management of hypertension.

These company claims the measurements are an improvement on conventional blood pressure measurements and can be applied in all research and clinical environments.

Website: www.uscom.com.au